MR-guided radiation therapy for early-stage kidney cancer in patients who can’t or won’t have surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will use an MR-guided linear accelerator to deliver radiation to early-stage renal cancer in adults who cannot have surgery or choose not to. The trial aims to collect data on how well the treatment works, the level of toxicity, and the precise dose distribution. The main goal is to determine if MRgRT has a better safety profile, particularly fewer grade 2+ adverse events, compared with conventional CT-based radiotherapy. Data from this study will inform whether MR guidance improves treatment tolerability while delivering effective dose to the tumor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients at or over 18 years old.
2. Patients may enter the study if they are diagnosed with bilateral kidney cancer, recurrent kidney cancer, or if they have previous or current history of a another primary cancer, given all other inclusion criteria met.
3. Have a pathologically confirmed diagnosis of renal cell carcinoma (RCC) of any histology, or radiographic diagnosis if biopsy is not clinically indicated, consistent with standard clinical practice where imaging findings provide sufficient diagnostic certainty. In such cases, biopsy may not be required to avoid additional procedural risk; however, inclusion of patients without histologic confirmation may introduce some diagnostic uncertainty, which will be considered in the interpretation of study results.
4. Patients must be deemed a suboptimal surgical or ablation candidate, as determined by the patient's primary urologist at NYU Langone Health and confirmed by multidisciplinary consensus, or may be individuals who decline surgery or ablation following appropriate clinical evaluation and discussion..

   o At or before the time of enrollment, a note documenting multidisciplinary consensus supporting active treatment will be recorded in the patient's chart.
5. Tumor stage of cT1a-b, cN0, M0 (i.e. less than 7 cm in greatest dimension).
6. Be technically and anatomically appropriate for MRI-guided radiation therapy, as determined by patient's primary radiation oncologist.

   o Factors considered will include distance between tumor and bowel, tumor movement with respiration as assessed by 4-dimensional (4D) imaging, and prior radiotherapy in close proximity to treatment which would lead to high dose overlap from the prior radiation fields.
7. Have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
8. Have life expectancy of 2 years or more.

Exclusion Criteria:

1. An MRI contraindication (e.g. severe claustrophobia or MRI-incompatible device). In the event of mild claustrophobia, patients will be permitted to take anti-anxiety medication as required for simulation and treatment.
2. A pre-treatment estimated glomerular filtration rate \< 30 cc/min.
3. Visceral, nodal, or bony metastatic disease.
4. Is pregnant or expecting to conceive within the projected duration of the trial at the screening visit.
5. Pregnant or breastfeeding individuals, or individuals of childbearing potential who have a positive pregnancy test at screening or prior to radiation treatment initiation.
6. Individuals of childbearing potential who are unwilling to use one highly effective method of contraception and one additional effective method of contraception, or abstain from heterosexual intercourse, during study participation and for 6 months after completion of study therapy.
7. Previous high dose radiation treatment to an overlapping area.
8. Has a diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation therapy.
9. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
10. Is on systemic therapy that is reasonably expected to modify radiation sensitivity and cannot be stopped for a sufficient washout period to allow for radiation treatment.

Where it's running

• NYU Langone Health
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Nicholas Colangelo, MD, PhD — NYU Langone Health
• Study coordinator: Nicholas Colangelo, MD, PhD
• Email: Nicholas.Colangelo@nyulangone.org
• Phone: 212-731-5003

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using semaglutide to manage high blood sugar after kidney transplants

  This study is testing if semaglutide can help manage high blood sugar in people who have recently had a kidney transplant, while also looking at its effects on weight and kidney function.

  Recruiting Phase 4 Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT05702931

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

• Hospital admissions for blood in the urine

  This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.

  Recruiting British Urology Researchers in Surgical Training · London · NCT07395037

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Spectral CT during embolization and ablation for liver and kidney tumors

  This pilot tries a new spectral CT technique during image-guided embolization and ablation for adults with liver or kidney tumors to see if it improves image quality and helps guide treatment.

  Recruiting Palo Alto Veterans Institute for Research · Palo Alto, California · NCT07303725

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.